Ekso Bionics Hlds

Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ekso Bionics reports record sales and margin growth in Q2 2024

Ekso Bionics delivered a strong performance in Q2 2024 with record sales, improved gross margins, and effective cost management.
The company's focus on expanding relationships, receiving Medicare reimbursement, and collaborations in neurorehabilitation centers position it well for growth.
While facing challenges in competitive industrial segments and margin sustainability, Ekso Bionics has opportunities to leverage international demand and market expansion.

Ekso Bionics reports solid Q3 performance, eyes global expansion

Ekso Bionics demonstrated solid performance in Q3 2024 with improved operational efficiency and strong international sales, despite challenges in the U.S. market.
The company's focus on market education, product reimbursement, and cost management positions it well for future growth and market expansion.
While facing challenges in achieving profitability and managing U.S. sales fluctuations, Ekso Bionics has opportunities to capitalize on its strengths and drive further growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sold Record Number of Annual EksoHealth Units in 2023 SAN RAFAEL, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023.

Ekso Bionics Reports Record Annual Revenue of $18.3 Million

Ekso Bionics (EKSO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Ekso Bionics (EKSO) Is a Great 'Buy the Bottom' Stock Now

ADMA Biologics

Inhibikase Therapeutics

ADMA, EKSO and IKT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 31, 2024.

Best Momentum Stocks to Buy for January 31st

Anavex Life Sciences

ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.

New Strong Buy Stocks for January 31st

Ekso Bionics (NASDAQ: EKSO ) stock is on the rise Friday without any clear news from the exoskeleton company this morning. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.

Why Is Ekso Bionics (EKSO) Stock Up 5% Today?

SAN RAFAEL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the launch of GaitCoach™, its next generation gait therapy software for EksoNR.

Ekso Bionics Launches GaitCoach Software for EksoNR

SAN RAFAEL, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2023.

Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results

SAN RAFAEL, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Company will participate at the Centers for Medicare & Medicaid Services' (“CMS”) Healthcare Common Procedure Coding System (“HCPCS”) public meeting on November 29, 2023, to discuss appropriate Medicare payment for the Ekso Indego Personal.

Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29

Ruling Could Significantly Expand Use of Ekso Indego Personal in Home and Community Markets SAN RAFAEL, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, announces that the Centers for Medicare & Medicaid Services (“CMS”) finalized its Calendar Year 2024 Home Health Prospective Payment System Rule CMS-1780 (“2024 Home Health Rule”), which includes exoskeletons in the Medicare brace benefit category.

Centers for Medicare & Medicaid Services (CMS) Codifies Medicare Coverage for Ekso Indego Personal

Ekso Bionics (EKSO) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.33 per share a year ago.

Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q3 2023 Earnings Call October 26, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Scott Davis - Chief Executive Officer Jason Jones - Chief Operating Officer Jerome Wong - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics Quarter Three 2023 Financial Results Call.

Ekso Bionics Holdings, Inc. (EKSO) Q3 2023 Earnings Call Transcript

SAN RAFAEL, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2023.

Ekso Bionics Reports Third Quarter 2023 Revenue Growth of 38%

SAN RAFAEL, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2023 after the close of trading on Thursday, October 26, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics to Report Third Quarter 2023 Financial Results on October 26, 2023

SAN RAFAEL, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, Chief Executive Officer, and Jerome Wong, Chief Financial Officer, will be participating in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference taking place in New York on September 11-13, 2023.

Ekso Bionics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q2 2023 Results Conference Call July 27, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Scott Davis - Chief Executive Officer Jason Jones - Chief Operating Officer Jerome Wong - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Hello, and welcome to the Ekso Bionics Q2 2023 Financial Results Conference Call and Webcast [Operator Instructions].

Ekso Bionics Holdings, Inc. (EKSO) Q2 2023 Earnings Call Transcript

Ekso Bionics (EKSO) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.23 per share a year ago.

Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates

SAN RAFAEL, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2023 after the close of trading on Thursday, July 27, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics to Report Second Quarter 2023 Financial Results on July 27, 2023

Ekso Bionics Holdings, Inc. (EKSO) Q1 2023 Earnings Call Transcript.

Ekso Bionics Holdings, Inc. (EKSO) Q1 2023 Earnings Call Transcript

Highest Quarterly Revenues in Company History SAN RAFAEL, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2023.

Ekso Bionics Announces 61% Increase in First Quarter 2023 Revenues

SAN RAFAEL, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2023 after the close of trading on Thursday, April 27, 2023. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

Ekso Bionics to Report First Quarter 2023 Financial Results on April 27, 2023

- SoldierStrong to Donate Device to the Charlie Norwood Department of Veteran Affairs Medical Center in Augusta, GA - SAN RAFAEL, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that SoldierStrong, a non-profit organization dedicated to improving Veterans' lives through innovative technology, has purchased an Ekso Indego Therapy device that it will donate to the Spinal Cord Injury Unit at Charlie Norwood VA Medical Center in Augusta, Georgia.

Ekso Bionics Announces Ekso Indego Therapy Order by SoldierStrong

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, FINN Partners Scott Davis - Chief Executive Officer Jason Jones - Chief Operating Officer Jerome Wong - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics Fourth Quarter 2022 Financial Results Conference Call.

Ekso Bionics Holdings, Inc. (EKSO) Q4 2022 Earnings Call Transcript

SAN RAFAEL, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2022.

Ekso Bionics Reports Fourth Quarter and Year End 2022 Results

SAN RAFAEL, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced it will showcase the new Ekso Indego Therapy with Functional Electrical Stimulation (FES) at the upcoming American Physical Therapy Association's Combined Sections Meeting on February 23-25 in San Diego, California. The Company recently filed a Premarket Notification 510(k) with the U.S. Food and Drug Administration that covers the addition of integrated FES hardware and software to Ekso Indego Therapy, a lower-limb powered exoskeleton recently acquired by Ekso.

Ekso Bionics to Showcase Integrated Functional Electrical Stimulation for Indego Therapy at APTA Meeting

Broadens Ekso Bionics' product portfolio into home use

News for Ekso Bionics Hlds Stock (EKSO)